biohacking$bioLLM CA: TBA

database / gh-secretagogue

Ipamorelin

research compound gh-secretagogue endocrine sequence not characterised
OOOOONNNNNNNNNHHHHHHHHHHH
52 heavy atoms · 104 bonds · drag to pan, scroll to zoom C38N9O5

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 9831659. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

Aib-His-D-2-Nal-D-Phe-Lys-NH2 — contains non-proteinogenic residues (Aib, D-2-Nal, D-Phe), so no standard one-letter sequence exists.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formulaC38H49N9O5
molecular weight711.9 Da (PubChem)
computed backbone massnot characterised
lengthnot characterised
net charge (pH 7.4)not characterised
mean hydropathynot characterised
half-lifenot characterised
delivery routenot characterised
PubChem CID9831659
PDBnot characterised
UniProt parentnot characterised

Mechanism

Selective ghrelin receptor (GHS-R1a) agonist; described as releasing GH with minimal effect on cortisol or prolactin.

Reported targets: GHS-R1a

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcomewhere it appears
GH releasePeptide Supplements and Their Therapeutic Applications in Sports Medicine The American journal of sports medicine 2026
IGF-1 elevationTherapeutic peptides in gerontology: mechanisms and applications for healthy… Frontiers in aging 2026

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCTtitlestatusphase
NCT00672074Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusCOMPLETEDPHASE2
NCT01280344Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FCOMPLETEDPHASE2
NCT07717866Trifecta Research StudyACTIVE_NOT_RECRUITING

Literature (8)

Peptide Supplements and Their Therapeutic Applications in Sports Medicine — The American journal of sports medicine 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42578445 · DOI 10.1177/03635465261464420

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — Frontiers in aging 2026

BackgroundPeptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.ObjectiveTo comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.MethodsA comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026. Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory docume…

open access ↗ · PMID 42021992 · DOI 10.3389/fragi.2026.1790247

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism — Physiology & behavior 2024

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 39043357 · DOI 10.1016/j.physbeh.2024.114644

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews 2026

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators, and neuroactive peptides like selank, semax, and dihexa enhance brain-derived n…

open access ↗ · PMID 41490200 · DOI 10.5435/jaaosglobal-d-25-00236

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — The American journal of sports medicine 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41476424 · DOI 10.1177/03635465251357593

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Preprints.org 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · DOI 10.20944/preprints202512.1011.v3

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41966639 · DOI 10.1007/s40279-026-02437-0

Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance — Preprints.org 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · DOI 10.20944/preprints202604.1748.v1

Related

Ghrelin

hormone · 8 citations

CJC-1295

gh-secretagogue · 8 citations

Sermorelin

gh-secretagogue · 8 citations

Tesamorelin

gh-secretagogue · 8 citations

GHRP-2

gh-secretagogue · 8 citations

GHRP-6

gh-secretagogue · 7 citations